In the long human struggle against cancer's tendency to hide until it is too late, a blood test called Galleri has offered a quietly remarkable signal: that the body's own shed genetic material may betray a tumour's presence long before symptoms sharpen into certainty. Trialled across thousands of NHS patients in England and Wales, the test correctly identified cancer in three quarters of suspected cases and located its origin with striking precision, though its power grows with the disease's advance. Researchers see in it not a replacement for existing vigilance, but a new instrument for the
Blood test shows promise detecting 50+ cancer types in NHS trial
A tool to expedite diagnosis and avoid invasive investigations
Mark
So this test found cancer in three-quarters of the people it was supposed to find it in. That sounds quite good. But what does that number actually mean for a patient walking into their GP's office?
Mimi
It means if you come in with symptoms that worry your doctor, and the test says you have cancer, there's a 75 percent chance you actually do. That's useful because it helps your GP move quickly toward the right diagnosis instead of ordering a bunch of other tests first.
Luke
But we should be clear about what population we're talking about. These were people who already had symptoms and had already gone to their GP. This isn't a screening test for healthy people. That's a different trial.
Mark
Right. So the test is good at confirming suspicion, not at finding hidden disease. What about the accuracy of pinpointing where the cancer is?
Mimi
The test identified the location of the cancer with 85 percent accuracy. That matters because it tells your oncologist where to look and what kind of treatment to plan for.
Luke
Though I'd want to know: in that 15 percent where it got the location wrong, how wrong was it? Did it point to the wrong organ entirely, or was it off by a region? The source doesn't say.
Mark
Fair point. What about the stage problem—the test was much worse at finding early cancers?
Mimi
Yes. It only caught 24 percent of stage one cancers but 95 percent of stage four. That's a real limitation if the whole point is catching cancer early.
Luke
Though early detection is exactly what they're testing in the asymptomatic trial. Maybe the test will perform differently when you're looking for cancers before symptoms develop. We won't know until later this year.
Mark
So this is promising, but incomplete.
Mimi
Exactly. It's a useful tool for doctors trying to figure out what's wrong with a symptomatic patient. But it's not a replacement for existing screening, and it's not yet proven as a way to find cancers before people feel sick.
Le Pouls
- Cancer's most dangerous advantage is time, and the Galleri test is designed to close that gap by reading tumour DNA fragments circulating silently in the blood.
- In a trial of over 6,000 NHS patients already presenting with symptoms, the test confirmed cancer in 244 of 323 flagged cases — a 75% hit rate — while locating the tumour's origin with 85% accuracy.
- A critical tension remains: the test catches only 24% of very early-stage cancers, yet surges to 95% accuracy for advanced disease, raising urgent questions about where it can do the most good.
- Clinicians argue the test's real power lies in primary care, where doctors face patients with vague, overlapping symptoms and must decide quickly whether to pursue a cancer pathway or look elsewhere.
- The NHS is now running a parallel trial on people with no symptoms at all, with results expected later this year — a test of whether Galleri can find what the body has not yet begun to announce.
In the long human struggle against cancer's tendency to hide until it is too late, a blood test called Galleri has offered a quietly remarkable signal: that the body's own shed genetic material may betray a tumour's presence long before symptoms sharpen into certainty. Trialled across thousands of NHS patients in England and Wales, the test correctly identified cancer in three quarters of suspected cases and located its origin with striking precision, though its power grows with the disease's advance. Researchers see in it not a replacement for existing vigilance, but a new instrument for the physician's hand — one that might spare patients the long, uncertain road between vague complaint and confirmed diagnosis.
A blood test called Galleri has shown it can detect more than fifty types of cancer in a large NHS trial across England and Wales, raising hopes for faster diagnosis in primary care settings. The test works by reading chemical signatures in fragments of tumour DNA that leak into the bloodstream, often before symptoms become clear.
In the Symplify trial, 6,238 people who had visited their GP with suspected cancer symptoms were enrolled. The test flagged cancer in 323 patients, of whom 244 were confirmed to have the disease — a positive predictive accuracy of 75 percent. It also identified where in the body the cancer had originated with 85 percent accuracy. Around 2 percent of those who tested negative were later found to have cancer regardless.
Effectiveness varied sharply by disease stage: detection rates fell to just 24 percent for early-stage tumours, but climbed to 95 percent for advanced cancers. Bowel cancer was the most commonly identified type at 37 percent of cases, followed by lung cancer at 22 percent and uterine cancer at 8 percent.
Oxford researcher Brian Nicholson described the findings as evidence that multi-cancer blood tests could help GPs move more quickly toward cancer evaluation for patients presenting with ambiguous symptoms such as weight loss or abdominal pain, potentially reducing both delays and unnecessary invasive investigations. The test does not replace existing screening programmes for breast, cervical, and bowel cancer.
Developed by California-based company Grail and already available in the United States, Galleri is now being trialled separately within the NHS to determine whether it can detect hidden cancers in people with no symptoms at all. Those results are expected later this year. The Symplify findings were presented at the American Society of Clinical Oncology conference in Chicago and published in The Lancet Oncology.
A blood test called Galleri has demonstrated the ability to detect more than fifty different cancer types in a trial of thousands of NHS patients in England and Wales, offering what researchers describe as a potentially significant tool for faster diagnosis in primary care.
The test works by identifying chemical signatures in fragments of genetic material that tumours shed into the bloodstream long before symptoms typically appear. In the Symplify trial, which enrolled 6,238 people who had visited their GP with suspected cancer symptoms, the test detected signs of disease in 323 patients. Of those, 244 were subsequently confirmed to have cancer—a positive predictive accuracy of 75 percent. The test also pinpointed where in the body the cancer originated with 85 percent accuracy. Around 2 percent of patients who tested negative were later found to have cancer anyway. Across the entire trial population, the test correctly identified cancer 66 percent of the time.
The test's effectiveness, however, depended heavily on how advanced the disease was. For very early-stage tumours, detection rates dropped to 24 percent. But for advanced cancers, the test caught 95 percent of cases. The most frequently diagnosed cancers in the trial were bowel cancer at 37 percent of cases, lung cancer at 22 percent, uterine cancer at 8 percent, oesophago-gastric cancer at 6 percent, and ovarian cancer at 4 percent.
Brian Nicholson, an associate professor at Oxford's Nuffield Department of Primary Care Health Sciences, framed the findings as evidence that multi-cancer blood tests could help primary care doctors move faster toward cancer evaluation rather than pursuing other diagnoses for patients presenting with vague symptoms like weight loss, anaemia, or abdominal pain. He noted that such tools could both speed up diagnosis and potentially spare patients from invasive and expensive investigations. The test does not, however, replace existing screening programmes for breast, cervical, and bowel cancer, and it does not detect all cancers.
The Galleri test, developed by California-based company Grail, is already available in the United States, where it has been recommended for people over 50 and those at higher risk. The NHS is now running a separate trial to determine whether the test can identify hidden cancers in people without any symptoms—results from that study are expected later this year. The Symplify findings were presented at the American Society of Clinical Oncology conference in Chicago and published in The Lancet Oncology.
Citations marquantes
New tools that can both expedite cancer diagnosis and potentially avoid invasive and costly investigations are needed to more accurately triage patients who present with non-specific cancer symptoms.— Brian Nicholson, associate professor at Oxford's Nuffield Department of Primary Care Health Sciences
Envie de l'histoire complète ?
Lire l'original sur RTE.ie ↗
Health & Medicine